We are live on ! Find out more
PCM

Penserra Capital Management Portfolio holdings

AUM $8.52B
1-Year Est. Return 37.76%
This Fund
S&P 500
This Quarter Est. Return
+9.48%
1 Year Est. Return
+37.76%
3 Year Est. Return
+116.32%
5 Year Est. Return
+122.1%
10 Year Est. Return
+1,892.45%
AUM
$5.41B
AUM Growth
+$1.18B
Cap. Flow
+$984M
Cap. Flow %
18.18%
Top 10 Hldgs %
20.49%
Holding
1,162
New
152
Increased
695
Reduced
244
Closed
54

Top Buys

Rank Stock Value
1
BABA icon
Alibaba
BABA
+$64.8M
2
JD icon
JD.com
JD
+$44.9M
3
MELI icon
Mercado Libre
MELI
+$40.5M
4
NTES icon
NetEase
NTES
+$38M
5
BEKE icon
KE Holdings
BEKE
+$21.5M

Top Sells

Rank Stock Value
1
FUTU icon
Futu Holdings
FUTU
+$21.6M
2
TCOM icon
Trip.com Group
TCOM
+$20.5M
3
AOD
abrdn Total Dynamic Dividend Fund
AOD
+$12.1M
4
GDV icon
Gabelli Dividend & Income Trust
GDV
+$12M
5
EFR
Eaton Vance Senior Floating-Rate Fund
EFR
+$11.2M

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 33.21%
2 Technology 22.71%
3 Communication Services 13.35%
4 Financials 4.97%
5 Industrials 4.84%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MGTX icon
1001
MeiraGTx Holdings
MGTX
$1.21B
$14K ﹤0.01%
985
-25
-2% -$391
XENE icon
1002
Xenon Pharmaceuticals
XENE
$6.12B
$14K ﹤0.01%
795
-10
-1% -$169
KDNY
1003
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$14K ﹤0.01%
960
-5
-0.5% -$82
ANAB icon
1004
AnaptysBio
ANAB
$1.68B
$13K ﹤0.01%
615
-15
-2% -$379
ARDX icon
1005
Ardelyx
ARDX
$997M
$13K ﹤0.01%
2,055
-15
-0.7% -$103
KALV
1006
DELISTED
KalVista Pharmaceuticals
KALV
$13K ﹤0.01%
530
+120
+29% +$3.15K
KNSA icon
1007
Kiniksa Pharmaceuticals
KNSA
$5.93B
$13K ﹤0.01%
720
-20
-3% -$409
RIGL icon
1008
Rigel Pharmaceuticals
RIGL
$750M
$13K ﹤0.01%
387
-16
-4% -$634
RLMD icon
1009
Relmada Therapeutics
RLMD
$527M
$13K ﹤0.01%
370
-5
-1% -$175
PSTX
1010
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$13K ﹤0.01%
1,400
-20
-1% -$196
ACIU icon
1011
AC Immune
ACIU
$240M
$12K ﹤0.01%
1,625
-20
-1% -$143
DNTH icon
1012
Dianthus Therapeutics
DNTH
$6.09B
$12K ﹤0.01%
68
-1
-1% -$168
DTIL icon
1013
Precision BioSciences
DTIL
$207M
$12K ﹤0.01%
40
– –
MSA icon
1014
Mine Safety
MSA
$7.49B
$12K ﹤0.01%
83
+8
+11% +$1.29K
RAPT
1015
DELISTED
RAPT Therapeutics
RAPT
$12K ﹤0.01%
70
-1
-1% -$165
EGRX
1016
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$12K ﹤0.01%
290
-10
-3% -$464
MRNS
1017
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$12K ﹤0.01%
810
+110
+16% +$1.59K
ISEE
1018
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$12K ﹤0.01%
2,035
-20
-1% -$121
AKBA icon
1019
Akebia Therapeutics
AKBA
$252M
$11K ﹤0.01%
3,480
+160
+5% +$576
ALT icon
1020
Altimmune
ALT
$599M
$11K ﹤0.01%
845
+85
+11% +$1.37K
AVDL
1021
DELISTED
Avadel Pharmaceuticals
AVDL
$11K ﹤0.01%
1,325
-135
-9% -$1.09K
CRNX icon
1022
Crinetics Pharmaceuticals
CRNX
$8.92B
$11K ﹤0.01%
745
-10
-1% -$155
CTMX icon
1023
CytomX Therapeutics
CTMX
$754M
$11K ﹤0.01%
1,475
+415
+39% +$3.29K
GERN icon
1024
Geron
GERN
$949M
$11K ﹤0.01%
7,105
-265
-4% -$473
NGNE icon
1025
Neurogene
NGNE
$712M
$11K ﹤0.01%
48
-1
-2% -$256
39 40
41
42 43

Similar funds

GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NB
Norinchukin Bank Tokyo, Japan $8.57B AUM 20.17% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
ACM
Advisors Capital Management Ridgewood, New Jersey $8.58B AUM 23.43% 1-Year Est. Return
FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Penserra Capital Management's Q1 2021 Portfolio in Review

As of Q1 2021, Penserra Capital Management held 1,162 positions worth $5.41B, up 28% from $4.23B the previous quarter. Its ten largest holdings account for 20% of the portfolio.

Penserra Capital Management deployed $984M of net new capital in Q1 2021, opening 152 new positions and adding to 695 existing holdings. Its largest new stake was BlackRock Resources & Commodities Strategy Trust: 1,847,500 shares worth $16.4M.

By sector, the portfolio is most concentrated in Consumer Discretionary at 33% of assets, down from 35% a quarter earlier, followed by Technology and Communication Services.

On the sell side, the largest reduction was Futu Holdings, an estimated $21.6M trimmed.

  • Penserra Capital Management's largest Q1 2021 buy was BlackRock Resources & Commodities Strategy Trust: 1,847,500 shares worth $16.4M.
  • Penserra Capital Management added most to Alibaba in Q1 2021, an estimated $64.8M increase.
  • Penserra Capital Management's biggest Q1 2021 reduction was Futu Holdings, cutting an estimated $21.6M.
  • Penserra Capital Management fully exited abrdn Total Dynamic Dividend Fund in Q1 2021, selling an estimated $12.1M.
  • Penserra Capital Management's ten largest holdings make up 20% of its $5.41B portfolio in Q1 2021.
  • Penserra Capital Management opened 152 new positions and closed 54 in Q1 2021.
  • Penserra Capital Management's portfolio value rose 28% quarter-over-quarter to $5.41B.

Based on Penserra Capital Management's 13F filing for Q1 2021, filed 13 May 2021.